|
|
|
| Effect of Tongxinluo Capsule combined with Irbesartan on Early Diabetic Nephropathy and Serum Levels of CysC IL-18 ET-1 and NO |
| WEI Hongfa, NING Jie, FENG Xiaoling |
| The Central Hospital in Longhua District of Shenzhen, Guangdong Shenzhen 518110, China |
|
|
|
|
Abstract Objective: To investigate the clinical efficacy of tongxinluo capsule combined with irbesartan (Irb) in the treatment of early diabetic kidney disease (DKD) and the effect on the serum cystatin C (CysC), interleukin (IL)-18, endothelin (ET)-1 and nitric oxide (NO) levels. Methods: 138 cases of patients with early DKD admitted in our hospital from Jan. 2015 to Jan. 2017 were selected and divided into two groups on a random basis. The control group was treated with Irb, while the observation group was administrated with tongxinluo capsule in combination with Irb. The clinical efficacy, changes of serum CysC, IL-18, ET-1, NO levels before and after treatment and occurrence of adverse reactions were compared between the two groups. Results: After 12 weeks of treatment, the total effective rate of the observation group was significantly higher than that of the control group (P<0.05). Compared with those before treatment, the serum CysC, IL-18 and ET-1 levels of both groups at 12 weeks after treatment were remarkably decreased(P<0.01), while the NO levels of both groups at 12 weeks after treatment were remarkably increased (P< 0.01). The serum CysC, IL-18 and ET-1 levels of observation group were significantly lower, while the serum NO level was much higher than those of the control group(P<0.01). There was no statistic difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combination of Tongxinluo capsule and erbesartan in the treatment of early DKD can effectively improve its clinical efficacy and improve renal function with high safety. It may significantly reduce the level of serum CysC, IL-18, ET-1, increase the level of serum NO, and then improve the microinflammatory state and vascular endothelial function of the body.
|
|
|
|
|
|
[1] Perezgomez M V, Sancheznino M D, Sanz A B, et al. Targeting inflammation in diabetic kidney disease: early clinical trials[J]. Expert Opin Investig Drugs, 2016, 25(9):1045~1058.
[2] Tsavdaridis I, Papadimitriou D, Karanikola D, et al. Sitagliptin reduces urinary microalbumin in experimental model of diabetic nephropathy[J]. Hell Nucl Med, 2015,18(Suppl1):154.
[3] Roscioni S S, Heerspink H J, De Z D. The effect of RAAS blockade on the progression of diabetic nephropathy[J]. Nat Rev Nephrol, 2014, 10(2):77~87.
[4] Pathak J V, Dass E E. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy[J]. Indian Pharmacol,2015, 47(2):148~152.
[5] Tian L, Liu J F, Gou Y L, et al. Effect of Tongxinluo capsule combined with irbesartan on renal function and endothelial function in the patients with early diabetic nephropathy[J]. Chin Diffic and Compl Cas, 2015, 14(6):615~617.
[6] Yassine H N, Olgica T, Dong Z, et al. The association of plasma cystatin C proteoforms with diabetic chronic kidney disease[J]. Proteome Sci, 2016, 14:7.
[7] Grzegorzewska A E, Ostromecki G, Zielińska P, et al. T-cell cytokine gene polymorphisms and vitamin D pathway gene polymorphisms in end-stage renal disease due to type 2 diabetes mellitus nephropathy: comparisons with health status and other main causes of end-stage renal disease[J].Diabetes Res, 2014, 2014:120317.
[8] Hsu Y, Lee P, Lei C, et al. Nitric oxide donors rescue diabetic nephropathy through oxidative-stress-and nitrosative-stress-mediated Wnt signaling pathways[J].Diabetes Investig, 2015, 6(1):24~34.
[9] Chinese Diabetes Society. Guidelines for prevention and treatment of type 2 diabetes in China (2013 Edition)[J]. Chin Diabetes Mellitus, 2014,6(7): 447~498.
[10] Microvascular complications group of Chinese Diabetes Society. Consensus on prevention and treatment of diabetic nephropathy (2014 Edition)[J]. Chin Diabetes Mellitus,2014, 6(11):792~801.
[11] Sourij H, Edlinger R, Prischl F, et al. Diabetic kidney disease-Update 2016[J]. Wien klin wochenschr, 2016, 128(Suppl 2):85~96.
[12] Wang D, Li Y X, Li J L. Treatment of diabetic nephropathy from spleen and kidney deficiency[J]. Liaoning Tradit Chin Med, 2017, 44(1):60~62. |
|
|
|
2018, Vol. 24 
